Literature DB >> 22800757

Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression.

George Anderson1, Michael Maes.   

Abstract

In 1995, the macrophage-T lymphocyte theory of schizophrenia (Smith and Maes, 1995) considered that activated immuno-inflammatory pathways may account for the higher neurodevelopmental pathology linked with gestational infections through the detrimental effects of activated microglia, oxidative and nitrosative stress (O&NS), cytokine-induced activation of the tryptophan catabolite (TRYCAT) pathway and consequent modulation of the N-methyl d-aspartate receptor (NMDAr) and glutamate production. The aim of the present paper is to review the current state-of-the art regarding the role of the above pathways in schizophrenia. Accumulating data suggest a powerful role for prenatal infection, both viral and microbial, in driving an early developmental etiology to schizophrenia. Models of prenatal rodent infection show maintained activation of immuno-inflammatory pathways coupled to increased microglia activation. The ensuing activation of immuno-inflammatory pathways in schizophrenia may activate the TRYCAT pathway, including increased kynurenic acid (KA) and neurotoxic TRYCATs. Increased KA, via the inhibition of the α7 nicotinic acetylcholine receptor, lowers gamma-amino-butyric-acid (GABA)ergic post-synaptic current, contributing to dysregulated glutamatergic activity. Hypofunctioning of the NMDAr on GABAergic interneurons will contribute to glutamatergic dysregulation. Many susceptibility genes for schizophrenia are predominantly expressed in early development and will interact with these early developmental driven changes in the immuno-inflammatory and TRYCAT pathways. Maternal infection and subsequent immuno-inflammatory responses are additionally associated with O&NS, including lowered antioxidants such as glutathione. This will contribute to alterations in neurogenesis and myelination. In such a scenario a) a genetic or epigenetic potentiation of immuno-inflammatory pathways may constitute a double hit on their own, stimulating wider immuno-inflammatory responses and thus potentiating the TRYCAT pathway and subsequent NMDAr dysfunction and neuroprogression; and b) antipsychotic-induced changes in immuno-inflammatory, TRYCAT and O&NS pathways would modulate the CNS glia-neuronal interactions that determine synaptic plasticity as well as myelin generation and maintenance.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22800757     DOI: 10.1016/j.pnpbp.2012.06.014

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  39 in total

Review 1.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

2.  Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy.

Authors:  Olakunle James Onaolapo; Olayemi Quyyom Ademakinwa; Temitayo Opeyemi Olalekan; Adejoke Yetunde Onaolapo
Journal:  Psychopharmacology (Berl)       Date:  2017-06-14       Impact factor: 4.530

Review 3.  In vivo imaging of neuroinflammation in schizophrenia.

Authors:  Ofer Pasternak; Marek Kubicki; Martha E Shenton
Journal:  Schizophr Res       Date:  2015-06-03       Impact factor: 4.939

4.  Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.

Authors:  Buranee Kanchanatawan; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; Heidi Ormstad; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-02-08       Impact factor: 5.590

5.  Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia.

Authors:  Kinga Szymona; Barbara Zdzisińska; Hanna Karakuła-Juchnowicz; Tomasz Kocki; Martyna Kandefer-Szerszeń; Marta Flis; Wojciech Rosa; Ewa M Urbańska
Journal:  Neurotox Res       Date:  2017-03-08       Impact factor: 3.911

6.  Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia.

Authors:  Buranee Kanchanatawan; Solaphat Hemrungrojn; Supaksorn Thika; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-09-05       Impact factor: 5.590

7.  Dietary zinc supplement militates against ketamine-induced behaviours by age-dependent modulation of oxidative stress and acetylcholinesterase activity in mice.

Authors:  Olakunle J Onaolapo; Olayemi R Jegede; Omolade Adegoke; Marufat O Ayinde; Oloruntola M Akeredolu; Adejoke Y Onaolapo
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

Review 8.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

9.  Reversible overexpression of bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in mice.

Authors:  Xiaoyang Luo; Wanxia He; Xiangyou Hu; Riqiang Yan
Journal:  Biol Psychiatry       Date:  2013-10-05       Impact factor: 13.382

10.  In Schizophrenia, Deficits in Natural IgM Isotype Antibodies Including those Directed to Malondialdehyde and Azelaic Acid Strongly Predict Negative Symptoms, Neurocognitive Impairments, and the Deficit Syndrome.

Authors:  Michael Maes; Buranee Kanchanatawan; Sunee Sirivichayakul; André F Carvalho
Journal:  Mol Neurobiol       Date:  2018-11-27       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.